Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
An analysis of profitability metrics between 2019 and 2023 reveals a general downward trend in efficiency and earnings capacity following a peak in 2020. While the company experienced a temporary increase in profitability across all ratios during 2020, subsequent years have been characterized by a steady contraction in margins and returns on invested capital.
- Profit Margin Analysis
- The operating profit margin peaked at 6.56% in 2020 before experiencing a sharp decline to 3.80% in 2021. Although a slight recovery to 4.11% occurred in 2022, the margin returned to 3.81% by 2023, indicating a stabilization at a lower threshold compared to 2019 levels. In contrast, the net profit margin has exhibited a more consistent and linear decline since 2020, falling from 4.43% to 2.36% by the end of 2023. The divergence between the stabilizing operating margin and the falling net margin suggests that non-operating expenses or tax burdens have placed increasing pressure on the final bottom line.
- Return on Equity (ROE)
- ROE demonstrated significant volatility, reaching a high of 24.53% in 2020. A substantial contraction occurred in 2021, with the ratio dropping to 18.24%. Following a period of relative stability in 2022, ROE declined further to 15.31% in 2023. This overall trajectory indicates a reduced ability to generate profit from shareholders' equity over the five-year period.
- Return on Assets (ROA)
- The ROA trend mirrors the pattern observed in ROE, peaking at 9.63% in 2020 before entering a sustained decline. The ratio fell to 6.61% in 2021 and continued to erode, reaching 5.29% by December 31, 2023. This downward movement suggests a decrease in asset utilization efficiency and a reduction in the profitability generated per unit of total assets.
In summary, the data indicates a period of peak profitability in 2020 followed by a multi-year decline. The simultaneous contraction of ROE, ROA, and net profit margins suggests a systemic reduction in overall financial performance and efficiency throughout the observed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Profit Margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Income from operations | 4,013) | 3,800) | 3,148) | 4,986) | 3,192) | |
| External revenues | 105,305) | 92,488) | 82,877) | 76,001) | 64,387) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 3.81% | 4.11% | 3.80% | 6.56% | 4.96% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | 16.15% | 19.16% | 19.56% | — | — | |
| Elevance Health Inc. | 4.47% | 4.94% | 5.15% | — | — | |
| Intuitive Surgical Inc. | 24.80% | 25.35% | 31.89% | — | — | |
| Medtronic PLC | 17.56% | 18.15% | 14.89% | — | — | |
| UnitedHealth Group Inc. | 8.80% | 8.83% | 8.40% | — | — | |
| Operating Profit Margin, Sector | ||||||
| Health Care Equipment & Services | 8.71% | 9.26% | 9.13% | — | — | |
| Operating Profit Margin, Industry | ||||||
| Health Care | 12.79% | 18.74% | 18.04% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Operating profit margin = 100 × Income from operations ÷ External revenues
= 100 × 4,013 ÷ 105,305 = 3.81%
2 Click competitor name to see calculations.
An analysis of the financial performance from 2019 to 2023 reveals a period of consistent top-line growth contrasted by volatility in operational efficiency. While external revenues expanded steadily throughout the five-year period, operating income and the resulting profit margins experienced significant fluctuations, indicating that revenue growth did not translate linearly into operational profit.
- External Revenue Growth
- A sustained upward trajectory in external revenues is observed, increasing from US$ 64,387 million in 2019 to US$ 105,305 million by December 31, 2023. This represents a consistent year-over-year expansion, reflecting a significant increase in the scale of business operations.
- Operating Income Volatility
- Income from operations exhibited non-linear movement. A peak occurred in 2020 at US$ 4,986 million, followed by a sharp contraction to US$ 3,148 million in 2021. A gradual recovery followed, with operating income rising to US$ 3,800 million in 2022 and reaching US$ 4,013 million in 2023. Despite the recovery, the 2023 figures remain below the 2020 peak despite substantially higher revenues.
- Operating Profit Margin Trends
- The operating profit margin reflects the underlying volatility in cost management relative to revenue. The margin peaked at 6.56% in 2020, coinciding with the highest operating income. However, a significant compression occurred in 2021, where the margin dropped to 3.80%. Although a slight improvement to 4.11% was noted in 2022, the margin returned to 3.81% in 2023. This suggests that the cost of generating revenue increased disproportionately during the latter part of the period, leading to a compression of the operational margin compared to 2019 and 2020 levels.
In summary, the trend indicates a divergence between revenue scaling and operational profitability. The ability to maintain the higher margins seen in 2020 was not sustained, and the organization has operated at a lower margin threshold of approximately 3.8% to 4.1% since 2021, despite a larger revenue base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Profit Margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Humana | 2,489) | 2,806) | 2,933) | 3,367) | 2,707) | |
| External revenues | 105,305) | 92,488) | 82,877) | 76,001) | 64,387) | |
| Profitability Ratio | ||||||
| Net profit margin1 | 2.36% | 3.03% | 3.54% | 4.43% | 4.20% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | 14.27% | 15.88% | 16.42% | — | — | |
| Elevance Health Inc. | 3.52% | 3.87% | 4.46% | — | — | |
| Intuitive Surgical Inc. | 25.24% | 21.25% | 29.85% | — | — | |
| Medtronic PLC | 12.03% | 15.90% | 11.97% | — | — | |
| UnitedHealth Group Inc. | 6.09% | 6.25% | 6.06% | — | — | |
| Net Profit Margin, Sector | ||||||
| Health Care Equipment & Services | 6.43% | 7.05% | 7.14% | — | — | |
| Net Profit Margin, Industry | ||||||
| Health Care | 11.49% | 14.65% | 15.24% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Net profit margin = 100 × Net income attributable to Humana ÷ External revenues
= 100 × 2,489 ÷ 105,305 = 2.36%
2 Click competitor name to see calculations.
A divergence is observed between revenue growth and bottom-line profitability from 2019 to 2023. While external revenues expanded consistently throughout the period, net income peaked in 2020 and subsequently declined, leading to a sustained compression of the net profit margin.
- External Revenue Trend
- External revenues demonstrated uninterrupted growth, increasing from 64,387 million USD in 2019 to 105,305 million USD in 2023. This reflects a consistent upward trajectory in top-line scale.
- Net Income Performance
- Net income attributable to the company rose to a peak of 3,367 million USD in 2020 but experienced a steady decrease over the subsequent three years, falling to 2,489 million USD by December 31, 2023.
- Net Profit Margin Analysis
- The net profit margin followed a pattern of initial growth followed by steady erosion. After reaching a high of 4.43% in 2020, the margin declined to 3.54% in 2021, 3.03% in 2022, and finally to 2.36% in 2023. This trend indicates that the growth in external revenues was offset by a more rapid increase in operating costs or other expenses, thereby reducing the overall efficiency of converting revenue into net profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Humana | 2,489) | 2,806) | 2,933) | 3,367) | 2,707) | |
| Stockholders’ equity | 16,262) | 15,311) | 16,080) | 13,728) | 12,037) | |
| Profitability Ratio | ||||||
| ROE1 | 15.31% | 18.33% | 18.24% | 24.53% | 22.49% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| Abbott Laboratories | 14.83% | 18.90% | 19.75% | — | — | |
| Elevance Health Inc. | 15.23% | 16.59% | 16.93% | — | — | |
| Intuitive Surgical Inc. | 13.51% | 11.98% | 14.32% | — | — | |
| Medtronic PLC | 7.30% | 9.59% | 7.01% | — | — | |
| UnitedHealth Group Inc. | 25.22% | 25.87% | 24.09% | — | — | |
| ROE, Sector | ||||||
| Health Care Equipment & Services | 17.13% | 18.40% | 17.28% | — | — | |
| ROE, Industry | ||||||
| Health Care | 19.40% | 24.82% | 25.44% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROE = 100 × Net income attributable to Humana ÷ Stockholders’ equity
= 100 × 2,489 ÷ 16,262 = 15.31%
2 Click competitor name to see calculations.
The financial trajectory from 2019 to 2023 indicates a compression in profitability relative to shareholders' equity. While the Return on Equity (ROE) reached a peak in 2020, a subsequent downward trend is observed, with the ratio declining to 15.31% by the end of 2023.
- Net Income Performance
- Net income attributable to the company peaked in 2020 at US$ 3,367 million. Following this peak, a consistent year-over-year decline was recorded, with net income falling to US$ 2,933 million in 2021, US$ 2,806 million in 2022, and reaching a period low of US$ 2,489 million in 2023.
- Equity Base Expansion
- Stockholders' equity exhibited a general growth pattern, increasing from US$ 12,037 million in 2019 to US$ 16,262 million in 2023. Despite a marginal decrease in 2022, the overall expansion of the equity base contributed to the dilution of the return ratio over the five-year period.
- ROE Analysis
- The decline in ROE is attributable to the simultaneous occurrence of falling net income and a rising equity base. The most pronounced contraction occurred between 2020 and 2021, where ROE dropped from 24.53% to 18.24%. Although the ratio remained stable in 2022 at 18.33%, it continued to erode in 2023, reflecting a diminished efficiency in generating profit from the available shareholder capital.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Assets (ROA)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Humana | 2,489) | 2,806) | 2,933) | 3,367) | 2,707) | |
| Total assets | 47,065) | 43,055) | 44,358) | 34,969) | 29,074) | |
| Profitability Ratio | ||||||
| ROA1 | 5.29% | 6.52% | 6.61% | 9.63% | 9.31% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| Abbott Laboratories | 7.82% | 9.31% | 9.40% | — | — | |
| Elevance Health Inc. | 5.50% | 5.86% | 6.26% | — | — | |
| Intuitive Surgical Inc. | 11.64% | 10.19% | 12.58% | — | — | |
| Medtronic PLC | 4.13% | 5.54% | 3.87% | — | — | |
| UnitedHealth Group Inc. | 8.18% | 8.19% | 8.15% | — | — | |
| ROA, Sector | ||||||
| Health Care Equipment & Services | 7.05% | 7.49% | 7.28% | — | — | |
| ROA, Industry | ||||||
| Health Care | 7.19% | 9.66% | 9.46% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROA = 100 × Net income attributable to Humana ÷ Total assets
= 100 × 2,489 ÷ 47,065 = 5.29%
2 Click competitor name to see calculations.
An analysis of the financial metrics from 2019 through 2023 reveals a significant decline in asset utilization efficiency. Although the organization experienced substantial asset growth, this expansion was not matched by corresponding increases in net income, resulting in a persistent downward trajectory for the return on assets (ROA).
- Net Income Trends
- Net income attributable to the company peaked in 2020 at US$ 3,367 million, following an initial increase from US$ 2,707 million in 2019. However, a steady decline occurred over the subsequent three years, with earnings decreasing to US$ 2,489 million by the end of 2023.
- Asset Base Expansion
- Total assets exhibited a strong upward trend, growing from US$ 29,074 million in 2019 to US$ 47,065 million in 2023. Aside from a slight contraction in 2022, the asset base expanded by approximately 62% over the five-year period.
- Return on Assets (ROA) Interpretation
- The ROA reached a maximum of 9.63% in 2020 before experiencing a sharp decline to 6.61% in 2021. This deterioration continued through 2023, closing at 5.29%. The compression of the ROA is a direct result of the divergence between shrinking net income and an expanding asset base, indicating a reduction in the company's ability to generate profit from its investments.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?